EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fatty acid transport protein 2 inhibition enhances glucose tolerance through α cell–mediated GLP-1 secretion

Shenaz Khan, Robert J Gaivin, Zhiyu Liu, Vincent Li, Ivy Samuels, Jinsook Son, Patrick Osei-Owusu, Jeffrey L Garvin, Domenico Accili, Jeffrey R Schelling

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci192011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Shenaz Khan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Glucagon-Secreting Cells, Fatty Acid Transport Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIDDK NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Glucagon-Secreting CellsFatty Acid Transport ProteinsAnimalsMiceHumansMice, KnockoutInsulinMaleDiabetes Mellitus, Type 2GlucagonMice, Inbred C57BLInsulin Secretion

Stichwörter der Autor:innen

Beta cellsEndocrinologyGlucose metabolismInsulinMetabolism

Substanzen

Glucagon-Like Peptide 1Fatty Acid Transport ProteinsInsulinGlucagon

Autor:innen und Institutionen

  • Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Louis Stokes Cleveland VA Medical Center, VA Northeast Ohio Healthcare System; Department of Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio, USA.
  • Department of Medicine and Naomi Berrie Diabetes Center, Vagelos College of Physicians and Surgeons of Columbia University, New York, New York, USA.
  • Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Förderung

  • BLRD VA
  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • National Institutes of Health

Zitieren

APA

Khan, S., Gaivin, R. J., Liu, Z., Li, V., Samuels, I., Son, J., Osei-Owusu, P., Garvin, J. L., Accili, D., & Schelling, J. R. (2025). Fatty acid transport protein 2 inhibition enhances glucose tolerance through α cell–mediated GLP-1 secretion. Journal of Clinical Investigation. https://doi.org/10.1172/jci192011

Vancouver

Khan S, Gaivin RJ, Liu Z, Li V, Samuels I, Son J, et al. Fatty acid transport protein 2 inhibition enhances glucose tolerance through α cell–mediated GLP-1 secretion. Journal of Clinical Investigation. 2025. doi:10.1172/jci192011

BibTeX
@article{Khan2025,
  author = {Khan, Shenaz and Gaivin, Robert J and Liu, Zhiyu and Li, Vincent and Samuels, Ivy and Son, Jinsook and Osei-Owusu, Patrick and Garvin, Jeffrey L and Accili, Domenico and Schelling, Jeffrey R},
  title = {Fatty acid transport protein 2 inhibition enhances glucose tolerance through α cell–mediated GLP-1 secretion},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci192011}
}
Kostenlos starten →